A Phase 3 interventional study of Dexmedetomidine hydrochloride in ICU Sedation, sponsored by Pfizer. Completed at 12 sites in Japan. Open to participants aged 45 Weeks to 16 Years. Per ClinicalTrials.gov, last updated 2018-12-17.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the efficacy, safety, and pharmacokinetics of dexmedetomidine given as continuous IV infusion in pediatric subjects [≥ 45 weeks CGA (corrected gestational age) to \<17 years old] requiring sedation under intensive care unit
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects who are judged by investigator or sub-investigator to have a neurological disease that will make sedation assessment difficult, such as:
Subjects with any of the following low blood pressure levels during the tests at the screening visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline
Drug: Dexmedetomidine hydrochloride
* 45 weeks CGA to \< 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state * 6 years old to \< 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state
Percentage of Participants Who Did Not Require a Rescue Sedative Within 24 Hours of Dosing of Study Drug
Percentage of participants who did not require rescue medication for Sedation (Midazolam) based on the data of investigator's judgement and State Behavioral Scale (SBS) (which was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation \[placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs\], the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation \[removal of endotracheal tube\], the target sedation depth was -1 to 0, where higher score indicated more responsive) were reported.
Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Percentage of Participants Who Did Not Require Administration of a Rescue Analgesic Within 24 Hours of Dosing of Study Drug
Percentage of participants who did not require administration of a rescue analgesic (Fentanyl) in addition to administration of the study drug based on investigator's judgement were reported.
Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Total Amount of Rescue Sedative Administered Within 24 Hours of Dosing of Study Drug
Total amount of rescue sedative (midazolam) administered Within 24 Hours of dosing of study drug.
Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Body Weight Adjusted Total Amount (Per Kg) of Rescue Sedative Taken Within 24 Hours of Dosing of Study Drug
Total amount of rescue sedative (midazolam) required within 24 hours of dosing of study drug. Dose was adjusted for body weight (mg divided by kg).
Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug
Total amount of rescue sedative (fentanyl) required Within 24 Hours of dosing of study drug.
Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Body Weight Adjusted Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug
Total amount of rescue analgesic (fentanyl) within 24 Hours of dosing of study drug. Dose was adjusted for body weight (mcg divided by kg).
Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Duration of Maintenance of Target Sedation Level Within 24 Hours of Dosing of Study Drug
Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the SBS. SBS was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more responsive.
Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Percentage of Maintenance Duration of Target Sedation Level Within 24 Hours of Dosing of Study Drug
Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.
Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Percentage of Participants Who Did Not Use a Rescue Sedative After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
Percentage of participants whose period of dosing of the investigational product exceeded 24 hours and who did not received rescue medication for Sedation (Midazolam) based on the data of investigator's judgement and SBS (which was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation \[placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs\], the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation \[removal of endotracheal tube\], the target sedation depth was -1 to 0, where higher score indicated more responsive) were reported.
Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Percentage of Participants Who Did Not Require Dosing of a Rescue Analgesic After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
Percentage of participants whose period of dosing of the investigational product exceeded 24 hours and who did not received rescue analgesic (Fentanyl) based on the investigator's judgement were reported.
Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Total Amount of Rescue Sedative Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
Total amount of rescue sedative (midazolam) administered after 24 hours of dosing of study drug.
Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Body Weight Adjusted Total Amount of Rescue Sedative Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
Total amount of rescue sedative (midazolam) required after 24 hours of dosing of study drug. Dose was adjusted for body weight (mg divided by kg).
Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Total Amount of Rescue Analgesic Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
Total amount of rescue analgesic (Fentanyl) administered by the participants after 24 hours of dosing of study drug.
Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Body Weight Adjusted Total Amount of Rescue Analgesic Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
Total amount of rescue analgesic (fentanyl) after 24 hours of dosing of study drug. Dose was adjusted for body weight (mcg divided by kg).
Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Duration of Maintenance of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more stability and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more stability.
Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Percentage of Maintenance Duration of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.
Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Duration of Maintenance of Target Sedation Level After Extubation
Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more responsive.
Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Percentage of Maintenance Duration of Target Sedation Level After Extubation
Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.
Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Total Amount of Rescue Sedative Taken After Extubation
Total amount of rescue sedative (Midazolam) administered by the participants after extubation.
Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Body Weight Adjusted Total Amount of Rescue Sedative Taken After Extubation
Total amount of rescue sedative (midazolam) administered by the participants after extubation. Dose was adjusted for body weight (mg divided by kg).
Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Total Amount of Rescue Analgesic Taken After Extubation
Total amount of rescue analgesic (fentanyl) administered by the participants after extubation.
Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Body Weight Adjusted Total Amount of Rescue Analgesic Taken After Extubation
Total amount of rescue analgesic (fentanyl) administered by the participants after extubation. Dose was adjusted for body weight (mcg divided by kg).
Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Median Time to Conclusion of Mechanical Ventilation
Time to conclusion of mechanical ventilation was defined as time duration from start of study drug administration until the end of mechanical ventilation.
Time frame: Baseline (start of study drug dosing) until end of mechanical ventilation (up to 28 days)
Number of Participants With Treatment- Emergent Adverse Events (AE) and Serious Adverse Events (SAE)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to up to 28 days after end of study drug dosing (up to 56 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both non-serious adverse events (AEs) and SAEs.
Time frame: Baseline up to 28 days after end of study drug dosing (up to 56 days)
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Vital signs included: systolic and diastolic blood pressure, heart rate, respiratory rate, percutaneous oxygen saturation, end-tidal carbon dioxide, core body temperature and body weight. Criteria for clinically significant vital signs abnormalities was based on Investigators decision.
Time frame: Baseline up to 28 days after end of study drug dosing (Day 56)
Number of Participants With Laboratory Test Abnormalities
Criteria for abnormality: hemoglobin, hematocrit and red blood cell count \<0.8\*lower limit of normal(LLN); platelet \<0.5\*LLN; \>1.75\*upper limit of normal(ULN); white blood cell count \<0.6\*LLN; \>1.5\*ULN; lymphocytes, neutrophils and stab cells \<0.8\*LLN; \>1.2\*ULN; eosinophils, basophils and monocytes \>1.2\*ULN; total bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase and gamma guanosine triphosphate and alkaline phosphatase \>3\*ULN; total protein and albumin \<0.8\*LLN; \>1.2\*ULN; glucose \<0.6\*LLN; \>1.5\*ULN; blood urea nitrogen and creatinine \>1.3\*ULN; uric acid \>1.2\*ULN; sodium \<0.95\*LLN; \>1.05\*ULN, potassium, calcium and magnesium \<0.9\*LLN; \>1.1\*ULN; phosphate \<0.8\*LLN; \>1.2\*ULN.
Time frame: Baseline up to 28 days after end of study drug dosing (Day 56)
Total Input/Output Fluid Volume
Total input fluid volume was defined as the quantity of total fluids administered and total output fluid volume was defined as the quantity of total fluids excreted or lost during the specified evaluation period.
Time frame: Baseline up to 28 days after end of study drug dosing (Day 56)
Incidence of Potential Withdrawal Symptoms
The potential withdrawal symptoms were defined as AEs that occurred or worsened after end of administration of dexmedetomidine. It included bradycardia, abdominal discomfort, abdominal pain, dry mouth, nausea, vomiting, injection site pain, pyrexia, body temperature increased, electrocardiogram QT prolonged, neuralgia, agitation, atelectasis, oropharyngeal pain and hypotension. Incidence of potential withdrawal symptoms was reported in terms of number of participants who had any of the mentioned withdrawal symptoms.
Time frame: Baseline up to 28 days after end of study drug dosing (Day 56)
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Criteria for clinically significant electrocardiogram abnormalities was based on Investigators decision.
Time frame: Baseline up to 28 days after end of study drug dosing (Day 56)
| Milestone | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years |
|---|---|---|---|---|
| Started | 14 | 18 | 19 | 12 |
| Completed | 14 | 18 | 17 | 12 |
| Not completed | 0 | 0 | 2 | 0 |
| Withdrew: Investigator's discretion | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
Percentage of participants who did not require rescue medication for Sedation (Midazolam) based on the data of investigator's judgement and State Behavioral Scale (SBS) (which was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation \[placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs\], the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation \[removal of endotracheal tube\], the target sedation depth was -1 to 0, where higher score indicated more responsive) were reported.
| percentage of participants | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Percentage of Participants Who Did Not Require a Rescue Sedative Within 24 Hours of Dosing of Study Drug | 78.6 (51.7 to 93.2) | 66.7 (43.6 to 83.9) | 78.9 (56.1 to 92.0) | 91.7 (62.5 to 100.0) | 77.8 (66.0 to 86.4) |
Percentage of participants who did not require administration of a rescue analgesic (Fentanyl) in addition to administration of the study drug based on investigator's judgement were reported.
| percentage of participants | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Percentage of Participants Who Did Not Require Administration of a Rescue Analgesic Within 24 Hours of Dosing of Study Drug | 85.7 (58.8 to 97.2) | 100.0 (79.3 to 100.0) | 94.7 (73.5 to 100.0) | 66.7 (38.8 to 86.4) | 88.9 (78.5 to 94.8) |
Total amount of rescue sedative (midazolam) administered Within 24 Hours of dosing of study drug.
| milligrams (mg) | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Total Amount of Rescue Sedative Administered Within 24 Hours of Dosing of Study Drug | 0.882 ± 0.8282 | 3.188 ± 1.6935 | 2.469 ± 1.3975 | 1.960 | 2.401 ± 1.5793 |
Total amount of rescue sedative (midazolam) required within 24 hours of dosing of study drug. Dose was adjusted for body weight (mg divided by kg).
| mg/kg | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Body Weight Adjusted Total Amount (Per Kg) of Rescue Sedative Taken Within 24 Hours of Dosing of Study Drug | 0.135 ± 0.1160 | 0.353 ± 0.2219 | 0.142 ± 0.0668 | 0.100 ± 0 | 0.228 ± 0.1866 |
Total amount of rescue sedative (fentanyl) required Within 24 Hours of dosing of study drug.
| micrograms | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug | 91.70 ± 78.772 | — | 97.50 ± 0 | 81.74 ± 15.754 | 86.84 ± 34.676 |
Total amount of rescue analgesic (fentanyl) within 24 Hours of dosing of study drug. Dose was adjusted for body weight (mcg divided by kg).
| mcg/kg | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Body Weight Adjusted Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug | 15.00 ± 9.899 | — | 5.00 ± 0 | 3.78 ± 1.311 | 7.16 ± 6.789 |
Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the SBS. SBS was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more responsive.
| hours | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Duration of Maintenance of Target Sedation Level Within 24 Hours of Dosing of Study Drug | 7.95 ± 7.191 | 3.89 ± 2.859 | 3.52 ± 5.495 | 2.96 ± 2.017 | 4.50 ± 5.112 |
Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.
| percentage of time | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Percentage of Maintenance Duration of Target Sedation Level Within 24 Hours of Dosing of Study Drug | 54.08 ± 31.825 | 60.97 ± 28.104 | 50.54 ± 27.898 | 62.25 ± 34.836 | 56.54 ± 29.911 |
Percentage of participants whose period of dosing of the investigational product exceeded 24 hours and who did not received rescue medication for Sedation (Midazolam) based on the data of investigator's judgement and SBS (which was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation \[placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs\], the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation \[removal of endotracheal tube\], the target sedation depth was -1 to 0, where higher score indicated more responsive) were reported.
| percentage of participants | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Percentage of Participants Who Did Not Use a Rescue Sedative After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation | 100.0 (29.0 to 100.0) | — | 100.0 (16.7 to 100.0) | — | 100.0 (38.3 to 100.0) |
Percentage of participants whose period of dosing of the investigational product exceeded 24 hours and who did not received rescue analgesic (Fentanyl) based on the investigator's judgement were reported.
| percentage of participants | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Percentage of Participants Who Did Not Require Dosing of a Rescue Analgesic After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation | 100.0 (29.0 to 100.0) | — | 100.0 (16.7 to 100.0) | — | 100.0 (38.3 to 100.0) |
Total amount of rescue sedative (midazolam) administered after 24 hours of dosing of study drug.
No measurements were reported for this outcome.
Total amount of rescue sedative (midazolam) required after 24 hours of dosing of study drug. Dose was adjusted for body weight (mg divided by kg).
No measurements were reported for this outcome.
Total amount of rescue analgesic (Fentanyl) administered by the participants after 24 hours of dosing of study drug.
No measurements were reported for this outcome.
Total amount of rescue analgesic (fentanyl) after 24 hours of dosing of study drug. Dose was adjusted for body weight (mcg divided by kg).
No measurements were reported for this outcome.
Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more stability and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more stability.
| hours | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Duration of Maintenance of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation | 0.81 ± 0.672 | — | 0.92 ± 0 | — | 0.84 ± 0.479 |
Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.
| percentage of time | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Percentage of Maintenance Duration of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation | 75.00 ± 35.355 | — | 100.00 ± 0 | — | 83.33 ± 28.868 |
Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more responsive.
| hours | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Duration of Maintenance of Target Sedation Level After Extubation | 11.68 ± 11.589 | 7.73 ± 7.543 | 7.60 ± 4.355 | 6.73 ± 5.036 | 8.42 ± 7.679 |
Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.
| Percentage of time | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Percentage of Maintenance Duration of Target Sedation Level After Extubation | 69.99 ± 28.260 | 53.93 ± 28.613 | 54.45 ± 30.805 | 55.82 ± 41.195 | 58.19 ± 31.829 |
Total amount of rescue sedative (Midazolam) administered by the participants after extubation.
| mg | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Total Amount of Rescue Sedative Taken After Extubation | 0.537 ± 0.3741 | 0.719 ± 0.3379 | 5.994 | — | 1.701 ± 2.4148 |
Total amount of rescue sedative (midazolam) administered by the participants after extubation. Dose was adjusted for body weight (mg divided by kg).
| mg/kg | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Body Weight Adjusted Total Amount of Rescue Sedative Taken After Extubation | 0.109 ± 0.0976 | 0.072 ± 0.0304 | 0.370 | — | 0.146 ± 0.1364 |
Total amount of rescue analgesic (fentanyl) administered by the participants after extubation.
| mcg | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Total Amount of Rescue Analgesic Taken After Extubation | — | — | 42.90 | — | 42.90 |
Total amount of rescue analgesic (fentanyl) administered by the participants after extubation. Dose was adjusted for body weight (mcg divided by kg).
| mcg/kg | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Body Weight Adjusted Total Amount of Rescue Analgesic Taken After Extubation | — | — | 3.00 | — | 3.00 |
Time to conclusion of mechanical ventilation was defined as time duration from start of study drug administration until the end of mechanical ventilation.
| hours | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Median Time to Conclusion of Mechanical Ventilation | 9.5 (6.3 to 17.5) | 6.0 (4.6 to 6.3) | 4.1 (3.0 to 6.0) | 4.5 (3.8 to 6.0) | 6.0 (4.8 to 6.2) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to up to 28 days after end of study drug dosing (up to 56 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both non-serious adverse events (AEs) and SAEs.
| Participants | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| AEs | 11 | 16 | 16 | 12 | 55 |
| SAEs | 0 | 0 | 1 | 0 | 1 |
Vital signs included: systolic and diastolic blood pressure, heart rate, respiratory rate, percutaneous oxygen saturation, end-tidal carbon dioxide, core body temperature and body weight. Criteria for clinically significant vital signs abnormalities was based on Investigators decision.
| Participants | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 | 0 | 0 | 0 |
Criteria for abnormality: hemoglobin, hematocrit and red blood cell count \<0.8\*lower limit of normal(LLN); platelet \<0.5\*LLN; \>1.75\*upper limit of normal(ULN); white blood cell count \<0.6\*LLN; \>1.5\*ULN; lymphocytes, neutrophils and stab cells \<0.8\*LLN; \>1.2\*ULN; eosinophils, basophils and monocytes \>1.2\*ULN; total bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase and gamma guanosine triphosphate and alkaline phosphatase \>3\*ULN; total protein and albumin \<0.8\*LLN; \>1.2\*ULN; glucose \<0.6\*LLN; \>1.5\*ULN; blood urea nitrogen and creatinine \>1.3\*ULN; uric acid \>1.2\*ULN; sodium \<0.95\*LLN; \>1.05\*ULN, potassium, calcium and magnesium \<0.9\*LLN; \>1.1\*ULN; phosphate \<0.8\*LLN; \>1.2\*ULN.
| Participants | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities | 13 | 18 | 15 | 11 | 57 |
Total input fluid volume was defined as the quantity of total fluids administered and total output fluid volume was defined as the quantity of total fluids excreted or lost during the specified evaluation period.
| milliliters (mL) | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Input Volume | 779.39 ± 342.617 | 799.18 ± 356.254 | 1023.60 ± 337.825 | 1415.96 ± 822.212 | 979.24 ± 520.514 |
| Output Volume | 975.06 ± 436.904 | 801.53 ± 353.379 | 1041.80 ± 356.375 | 1313.58 ± 625.474 | 1009.58 ± 461.471 |
The potential withdrawal symptoms were defined as AEs that occurred or worsened after end of administration of dexmedetomidine. It included bradycardia, abdominal discomfort, abdominal pain, dry mouth, nausea, vomiting, injection site pain, pyrexia, body temperature increased, electrocardiogram QT prolonged, neuralgia, agitation, atelectasis, oropharyngeal pain and hypotension. Incidence of potential withdrawal symptoms was reported in terms of number of participants who had any of the mentioned withdrawal symptoms.
| Participants | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Bradycardia | 0 | 4 | 0 | 0 | 4 |
| Abdominal discomfort | 0 | 0 | 1 | 0 | 1 |
| Abdominal pain | 0 | 0 | 0 | 1 | 1 |
| Dry mouth | 0 | 0 | 1 | 0 | 1 |
| Nausea | 0 | 0 | 2 | 3 | 5 |
| Vomiting | 1 | 1 | 1 | 4 | 7 |
| Injection site pain | 0 | 0 | 0 | 1 | 1 |
| Pyrexia | 1 | 0 | 0 | 0 | 1 |
| Body temperature increased | 1 | 0 | 0 | 0 | 1 |
| Electrocardiogram QT prolonged | 0 | 0 | 1 | 0 | 1 |
| Neuralgia | 0 | 0 | 0 | 1 | 1 |
| Agitation | 1 | 1 | 1 | 0 | 3 |
| Atelectasis | 1 | 1 | 0 | 0 | 2 |
| Oropharyngeal pain | 0 | 0 | 0 | 1 | 1 |
| Hypotension | 0 | 1 | 1 | 1 | 3 |
Criteria for clinically significant electrocardiogram abnormalities was based on Investigators decision.
| Participants | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 | 0 | 0 |
Collected over Baseline up to 28 days after end of study drug dosing (Day 56). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dexmedetomidine: >=45 Weeks CGA to <12 Months | 0/14 (0%) | 0/14 (0%) | 11/14 (78.6%) |
| Dexmedetomidine: >=12 Months to <24 Months | 0/18 (0%) | 0/18 (0%) | 16/18 (88.9%) |
| Dexmedetomidine: >=2 Years to <6 Years | 0/19 (0%) | 1/19 (5.3%) | 16/19 (84.2%) |
| Dexmedetomidine: >=6 Years to <17 Years | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| Dexmedetomidine: All Participants | 0/63 (0%) | 1/63 (1.6%) | 55/63 (87.3%) |
| Event | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| Cardiac tamponadeCardiac disorders | 0/14 | 0/18 | 1/19 | 0/12 | 1/63 |
| Event | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Dexmedetomidine: All Participants |
|---|---|---|---|---|---|
| HypotensionVascular disorders | 3/14 | 8/18 | 11/19 | 9/12 | 31/63 |
| BradycardiaCardiac disorders | 6/14 | 7/18 | 5/19 | 2/12 | 20/63 |
| VomitingGastrointestinal disorders | 1/14 | 1/18 | 2/19 | 5/12 | 9/63 |
| NauseaGastrointestinal disorders | 0/14 | 0/18 | 2/19 | 5/12 | 7/63 |
| Respiratory depressionRespiratory, thoracic and mediastinal disorders | 2/14 | 7/18 | 3/19 | 5/12 | 17/63 |
| AgitationPsychiatric disorders | 4/14 | 2/18 | 1/19 | 0/12 | 7/63 |
| PyrexiaGeneral disorders | 1/14 | 2/18 | 1/19 | 2/12 | 6/63 |
| Body temperature increasedInvestigations | 1/14 | 2/18 | 0/19 | 0/12 | 3/63 |
| Abdominal painGastrointestinal disorders | 0/14 | 0/18 | 0/19 | 1/12 | 1/63 |
| Injection site painGeneral disorders | 0/14 | 0/18 | 0/19 | 1/12 | 1/63 |
The Full Analysis Set (FAS) included all participants who have received at least one dose of the study drug.
| Age, Continuous(months) | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Total |
|---|---|---|---|---|---|
| Mean | 6.1 ± 2.1 | 16.9 ± 3.6 | 45.7 ± 14.6 | 112.1 ± 37.9 | 41.3 ± 41.8 |
| Sex: Female, Male(Participants) | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Total |
|---|---|---|---|---|---|
| Female | 8 | 7 | 7 | 5 | 27 |
| Male | 6 | 11 | 12 | 7 | 36 |
| Race (NIH/OMB)(Participants) | Dexmedetomidine: >=45 Weeks CGA to <12 Months | Dexmedetomidine: >=12 Months to <24 Months | Dexmedetomidine: >=2 Years to <6 Years | Dexmedetomidine: >=6 Years to <17 Years | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 14 | 18 | 19 | 12 | 63 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in May 2017, 10 months.
Results were first posted in Dec 2018, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine